NCT04149145 is a phase I trial of niraparib in combination with the ATR inhibitor M4344 among patients with PARPi-resistant, recurrent ovarian cancer and was anticipated to begin enrollment in December 2022 (NCT04149145). The gene discussed is ATR; the disease is ovarian carcinoma.